Xencor Inc (NAS:XNCR)
$ 25.6 -0.02 (-0.08%) Market Cap: 1.79 Bil Enterprise Value: 1.34 Bil PE Ratio: 0 PB Ratio: 2.47 GF Score: 63/100

Xencor Inc at Barclays Global Healthcare Conference Transcript

Mar 14, 2023 / 06:05PM GMT
Release Date Price: $28.27 (-0.49%)
Peter Richard Lawson
Barclays Bank PLC, Research Division - Research Analyst

Good afternoon. Welcome to Barclays Healthcare Global Conference. And of course, you can e-mail me and my associates if you have questions. But -- my name is Peter Wilson. I'm one of the biotech analysts at Barclays covering mid-cap oncology, and really delighted to have with us the CEO from Xencor, Bassil Dahiyat.

Questions & Answers

Peter Richard Lawson
Barclays Bank PLC, Research Division - Research Analyst

And I guess the first thing really for me is always like fantastic breadth of development over the years, like the way you kind of view your technology in that antibody space and kind of how it differentiates. I know now it has kind of changed to a certain degree because you're thinking bispecifics, et cetera.

But just kind of what's the differentiation within that core that pharma companies want to partner with you?

Bassil I. Dahiyat
Xencor, Inc. - Co-Founder, CEO, President & Director

So the issue of

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot